pharma logo_2010

Based upon his decades of successful product development experience, Gary D. Novack, Ph.D., president and founder of PharmaLogic Development, Inc., can help you develop a strategic plan for your product. Once planned, he and his team of experts can help you execute that plan. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).



Calvert Labs is an early-stage development partner offering a wide range of lead identification, lead optimization and preclinical services to meet your R&D needs. Calvert has made significant contributions to numerous IND and NDA applications worldwide, many which are now commercially marketed therapeutics. Calvert Labs’ unparalleled expertise spans across multiple therapeutic areas, including ophthalmology, where Calvert is highly regarded in the marketplace. In addition to Calvert’s 30-year heritage in ocular development, they have enjoyed a 20 plus year partnership with Cornell University veterinary ophthalmologist, Thomas J. Kern, DVM, who helped develop intravitreal and subconjunctival techniques at Calvert. These ground-breaking techniques and Calvert’s highly qualified management team set the foundation for the commercial success of numerous ocular therapeutics, including Macugen, which became the first anti-VEGF inhibitor to be approved by the FDA for the treatment of wet AMD.

The University of Oklahoma Health Sciences Center – EyeCRO works closely with the University of Oklahoma Health Sciences Center. This partnership allows EyeCRO to keep costs low, while providing a benefit to the university, and our clients.

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Preclinical Ophthalmic Contract Research